MCU Phase 3 raised the bar in every possible way. The fights looked better. The stakes felt heavier. The damage hit harder.

Key results from the interim analysis of the Phase 3 ENLIGHTED study of Padeliporfin VTP: As of November 5, 2024, the data ...

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Vincent Picozzi, MD, medical oncologist and director of the Pancreaticobiliary Program at Virginia Mason, discusses findings ...

Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the ...

Summit has been a tremendous winner over the past year, as its bispecific antibody lung cancer drug ivonescimab outperformed ...

NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc.

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

A SpaceX launch of a GPS satellite Friday marked the latest national security mission taken away from United Launch Alliance ...

In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...